⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL104509 | 0.65 | — | — | |
| SCHEMBL14697593 | 0.64 | DRD2 (0.34) | — | |
| SCHEMBL857945 | 0.64 | — | — | |
| SCHEMBL4918593 | 0.61 | — | — | |
| SCHEMBL154827 | 0.61 | SIGMAR1 (0.40) | — | |
| SCHEMBL18510121 | 0.60 | NOTUM (0.42) | — | |
| SCHEMBL7834708 | 0.60 | — | — | |
| SCHEMBL3787549 | 0.60 | — | — | |
| SCHEMBL2656107 | 0.60 | — | — | |
| SCHEMBL288679 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035950-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | claimed |
| US-20190127380-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-02 | — | — | US | claimed |
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | claimed |
| WO-2017184662-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-26 | — | — | WO | claimed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | claimed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | claimed |
| US-20240173419-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024092009-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024092011-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024064080-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-113226310-B | 15-PGDH inhibitors | 杏林制药株式会社 | 2024-03-19 | — | — | CN | disclosed |
| WO-2024039901-A2 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-1022274-A1 | Oxazolidinedione and Thiazolidinedione derivatves, their preparation and their use | Sankyo Company Limited (JP) | 2000-07-26 | — | — | EP | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5962470-A | Heterocyclic compounds having anti-diabetic activity and their use | SANKYO COMPANY, LIMITED (JP) | 1999-10-05 | — | — | US | disclosed |
| US-5834501-A | TREATING DIABETES OR HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 1998-11-10 | — | — | US | disclosed |
| US-5739345-A | HYPOGLYCEMIC AND ANTIDIABETIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |